Increased HDL size and enhanced apo A-I catabolic rates are associated with doxorubicin-induced proteinuria in New Zealand white rabbits

Lipids

Volumn 51, Issue 3, 2016, Pages 311-320

  López Olmos, Victoria ^a   Carreón Torres, Elizabeth ^a   Luna Luna, María ^a   Flores Castillo, Cristobal ^a   Martínez Ramírez, Miriam ^a   Bautista Pérez, Rocío ^a   Franco, Martha ^a   Sandoval Zárate, Julio ^a   Roldán, Francisco Javier ^a   Aranda Fraustro, Alberto ^a   Soria Castro, Elizabeth ^a   Muñoz Vega, Mónica ^a   Fragoso, José Manuel ^a   Vargas Alarcón, Gilberto ^a   Pérez Méndez, Oscar ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

Atherosclerosis; Coronary heart disease; HDL; Lipoprotein metabolism; Paraoxonase 1; Renal failure

Indexed keywords

APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE 1; CREATININE; DOXORUBICIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 2A; HIGH DENSITY LIPOPROTEIN 2B; HIGH DENSITY LIPOPROTEIN 3A; HIGH DENSITY LIPOPROTEIN 3B; HIGH DENSITY LIPOPROTEIN 3C; IODINE 131; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOTOXICITY; CATABOLISM; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININEMIA; ELECTROPHORESIS; ENZYME ACTIVITY; HEART INJURY; HISTOPATHOLOGY; ISOTOPE LABELING; KIDNEY INJURY; MALE; NEW ZEALAND WHITE (RABBIT); NONHUMAN; PROTEIN URINE LEVEL; PROTEINURIA; TRIACYLGLYCEROL BLOOD LEVEL; UREMIA; ANIMAL; CHEMICALLY INDUCED; CHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PARTICLE SIZE; RABBITS AND HARES;

ADMINISTRATION, INTRAVENOUS; ANIMALS; APOLIPOPROTEIN A-I; DOXORUBICIN; LIPOPROTEINS, HDL; MALE; PARTICLE SIZE; PROTEINURIA; RABBITS;

EID: 84959922904     PISSN: 00244201     EISSN: 15589307     Source Type: Journal    
DOI: 10.1007/s11745-016-4120-6     Document Type: Article

References (46)

1. Tran-Dinh A, Diallo D, Delbosc S, Varela-Perez LM, Dang QB, Laupergue B, Burillo E, Michel JB, Levoye A, Martín-Ventura JL, Meilhac O (2013) HDL and endothelial protection. Br J Pharmacol 169:493-511
2. Lee JY, Lanningham-Foster L, Boudyguina EY, Smith TL, Young ER, Colvin PL, Thomas MJ, Parks JS (2004) Prebeta-high density lipoprotein has two metabolic fates in human apolipoprotein AI transgenic mice. J Lipid Res 45:716-728
3. Castro GR, Fielding CJ (1988) Early incorporation of cell-derived cholesterol into pre-beta-migrating high density lipoprotein. Biochemistry 12:25-29
4. Deakin S, Leaviev I, Gomaraschi M, Calabresi I, Franceschini G, James RW (2002) Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J Biol Chem 277:4301-4308
5. Kontush A, Chantepie S, Chapman MJ (2003) Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Throm Vasc Biol 23:1881-1888
6. Pérez-Méndez O, Pacheco HG, Martínez-Sánchez C, Franco M (2014) HDL-cholesterol in coronary artery disease risk: function or structure? Clin Chim Acta 429:111-122
7. Toledo-Ibelles P, Franco M, Carreón-Torres E, Luc G, Tailleux A, Vargas-Alarcón G, Fragoso JM, Aguilar-Salinas C, Luna-Luna M, Pérez-Méndez O (2013) Normal HDL-apo AI turnover and cholesterol enrichment of HDL subclasses in New Zealand rabbits with partial nephrectomy. Metabolism 62:492-498
8. Graversen JH, Castro G, Kandoussi A, Nielsen H, Christensen EI, Norden A, Moestrup SK (2008) A pivotal role of the human kidney in catabolism of HDL protein components apolipoprotein AI and A-IV but not of A-II. Lipids 43:467-470
9. Kaysen GA (2009) Lipid and lipoprotein metabolism in chronic kidney disease. J Ren Nutr 19:73-77
10. Soto-Miranda E, Carreón-Torres E, Lorenzo K, Bazán-Salinas B, García-Sánchez C, Franco M, Posadas-Romero C, Fragoso JM, López-Olmos V, Madero M, Rodríguez-Pérez JM, Vargas-Alarcón G, Pérez-Méndez O (2012) Shift of high-density lipoprotein size distribution toward large particles in patients with proteinuria. Clin Chim Acta 414:241-245
11. Lamarche B, Uffelman KD, Steiner G, Barrett PH, Lewis GF (1998) Analysis of particle size and lipid composition as determinants of the metabolic clearance of human high density lipoprotein in a rabbits model. J Lipid Res 39:1162-1172
12. Lewis GF, Lamarche B, Uffelman KD, Heatherigton AC, Honing MA, Szeto LW, Barrett PH (1997) Clearance of postprandial and lipolytically modified human HDL in rabbits and rats. J Lipid Res 38:1771-1778
13. Kamgang R, Foyet AF, Essame JL, Ngogang JY (2012) Effect of methanolic fraction of Kalanchoe crenata on metabolic parameters in adriamycin-renal induced impairment in rats. Indian J Pharmacol 44:566-570
14. Khurana S, Bruggeman LA, Kao HY (2012) Nuclear hormone receptors in podocytes. Cell Biosci 2:33
15. Watanabe N, Kamei S, Ohkubo A, Yamanaka M, Ohsawa S, Makino K, Tokuda K (1986) Urinary protein as measured with a pyrogallol red-molybdate complex, manually and in a Hitachi 726 automated analyzer. Clin Chem 32:1551-1554
16. Matsuo S, Fukatsu A, Taub ML, Caldwell PR, Brentjens JR, Andres G (1987) Glomerulonephritis induced in the rabbit by antiendothelial antibodies. J Clin Invest 79:1798-1811
17. Huesca-Gómez C, Franco M, Luc G, Montaño LF, Massó F, Posadas-Romero C, Pérez-Méndez O (2002) Chronic hypothyroidism induces abnormal structure of high-density lipoproteins and impaired kinetics of apolipoprotein A-I in the rat. Metabolism 51:443-450
18. Toledo-Ibelles P, García-Sánchez C, Ávila-Vazzini N, Carreón-Torres E, Posadas-Romero C, Vargas-Alarcón G, Pérez-Méndez O (2010) Enzymatic assessment of cholesterol on electrophoresis gels for estimating HDL size distribution and plasma concentrations of HDL subclasses. J Lipid Res 51:1610-1617
19. García-Sánchez C, Torres-Tamayo M, Juárez-Meavepeña M, López-Osorio C, Toledo-Ibelles P, Monter-Garrido M, Cruz-Robles D, Carreón-Torres E, Vargas-Alarcón G, Pérez-Méndez O (2011) Lipid plasma concentrations of HDL subclasses determined by enzymatic staining on polyacrylamide electrophoresis gels in children with metabolic syndrome. Clin Chim Acta 412:292-298
20. Juárez-Meavepeña M, Carreón-Torres E, López-Osorio C, García-Sánchez C, Gamboa R, Torres-Tamayo M, Fragoso JM, Rodríguez-Pérez JM, Vargas-Alarcón G, Pérez-Méndez O (2012) The Srb1 + 1050T allele is associated with metabolic syndrome concentrations of high-density lipoprotein subclasses. Metab Syndr Relat Disord 10:110-116
21. Williams PT, Krauss RM, Nichols AV, Vranizan KM, Wood PD (1990) Identifying the predominant peak diameter of high-density and low-density lipoproteins by electrophoresis. J Lipid Res 31:1131-1139
22. Tailleux A, Torpier G, Caron B, Fruchart JC, Fievet C (1993) Immunological properties of apoB-containing lipoprotein particles in human atherosclerotic arteries. J Lipid Res 34:719-728
23. Gan KN, Smolen A, Eckerson HW, La Du BN (1991) Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 19:100-106
24. Skutelsky E, Hartzan S, Socher R, Gafter U (1995) Modifications in glomerular polyanion distribution in adriamycin nephrosis. J Am Soc Nephrol 5:1799-1805
25. He L, Hao L, Fu X, Huang M, Li R (2015) Severe hypertriglyceridemia and hypercholesterolemia accelerating renal injury: a novel model of type 1 diabetic hamsters induced by short-term high-fat/high-cholesterol diet and low-dose streptozotocin. BMC Nephrol 16:51
26. Aizawa K, Takeda S, Tashiro Y, Yorozu K, Hirata M, Kanada H, Moriguchi Y, Endo K (2012) Renoprotection by continuous erythropoietin receptor activator in puromycin aminonucleoside-induced nephrotic syndrome. Am J Nephrol 36:419-426
27. Bulum T, Kolaric B, Duvnjak L (2013) Lower levels of total HDL and HDL3 cholesterol are associated with albuminuria in normoalbuminuric type 1 diabetic patients. J Endocrinol Invest 36:574-578
28. Kaysen GA, Hoye E, Jones H Jr (1995) Apolipoprotein AI levels are increased in part as a consequence of reduced catabolism in nephrotic rats. Am J Physiol 268:F532-F540
29. Marsche G, Saemann MD, Heinemman A, Holzer M (2013) Inflammation alters HDL composition and function: implications for HDL-raising therapies. Pharmacol Ther 137:341-351
30. Festa A, Williams K, Hanley AJ, Otvos JD, Goff DC, Wagenknecht LE, Haffner SM (2005) Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study. Circulation 111:3465-3472
31. Van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ES, Tikkanen MJ, Wareham NJ, Faergeman O, Olsson AG, Pedersen TR, Khaw KT, Kastelein JJ (2008) High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPICNorfolk studies. J Am Coll Cardiol 51:634-642
32. Keane WF, Tomassini JE, Neff DR (2013) Lipid abnormalities in patients with chronic kidney disease: implications for the pathophysiology of atherosclerosis. J Atheroscler Thromb 20:123-133
33. Scarpioni R, Ricardi M, Albertazzi V, Melfa L (2012) Treatment of dyslipidemia in chronic kidney disease: effectiveness and safety of statins. World J Nephrol 1:184-194
34. Saku K, Mendoza SG, Laver M, Hynd BA, Gartside PS, Kashyap ML (1988) High-density lipoprotein apolipoprotein AI and AII turnover in moderate and severe proteinuria. Nephron 50:112-115
35. Vaziri ND (2003) Molecular mechanisms of lipid disorders in nephrotic syndrome. Kidney Int 63:1964-1976
36. Elkhalil L, Majd Z, Bakir R, Perez-Mendez O, Castro G, Poulain P, Lacroix B, Duhal N, Fruchart JC, Luc G (1997) Fish-eye disease: structural and in vivo metabolic abnormalities of high-density lipoproteins. Metabolism 46:474-483
37. Carreón-Torres E, Rendón-Sauer K, Monter-Garrido M, Toledo-Ibelles P, Gamboa R, Menjivar M, López-Marure R, Luc G, Fievet C, Cruz D, Vargas-Alarcón G, Pérez-Méndez O (2009) Rosiglitazone modifies HDL structure and increases HDL-apo AI synthesis and catabolic rates. Clin Chim Acta 401:37-41
38. Razavi AE, Ani M, Pourfarzam M, Naderi GA (2012) Associations between high density lipoprotein mean particle size and serum paraoxonase-1 activity. J Res Med Sci 17:1020-1026
39. Gugliucci A, Caccavello R, Kotani K, Sakane N, Kimura S (2013) Enzymatic assessment of paraoxonase 1 activity on HDL subclasses: a practical zymogram method to assess HDL function. Clin Chim Acta 415:162-168
40. Kennedy DJ, Tang WH, Fan Y, Wu Y, Mann S, Pepoy M, Hazen SL (2013) Diminished antioxidant activity of high-density lipoprotein-associated proteins in chronic kidney disease. J Am Heart Assoc 2:e000104
41. Kashyap ML, Srivastava LS, Hynd BA, Brady D, Perisutti G, Glueck CJ, Gartside PS (1980) Apolipoprotein CII and lipoprotein lipase in human nephrotic syndrome. Atherosclerosis 35:29-40
42. Yamada M, Matsuda I (1970) Lipoprotein lipase in clinical and experimental nephrosis. Clin Chim Acta 30:787-794
43. Hirano T, Ebara T, Furukawa S, Nagano S, Takahashi T (1994) Mechanism of hypertriglyceridemia in Dahl salt-sensitive rats, an animal model of spontaneous nephrotic syndrome. Metabolism 43:248-256
44. Pérez-Méndez O, Alvarez-Salcedo P, Carreón-Torres E, Luc G, Arce Fonseca M, de la Peña A, Cruz Robles D, García JJ, Vargas-Alarcón G (2007) Palmitic acid in HDL is associated to low apo A-I fractional catabolic rates in vivo. Clin Chim Acta 78:53-58
45. Pérez-Méndez O, Carreón-Torres E, Franco M, Juárez-Oropeza MA (2009) HDL physicochemical characteristics as determinants of their plasma concentrations: what we have learned from thiazolidinediones. In: Pagano IS (ed) HDL and LDL cholesterol: physiology and clinical significance. Strait NB Nova Science, New York
46. Okubo K, Ikewaki K, Sakai S, Tada N, Kawaguchi Y, Mochizuki S (2004) Abnormal HDL apolipoprotein A-I and A-II kinetics in hemodialysis patients: a stable isotope study. J Am Soc Nephrol 15:1008-1015